Finance

Lists
603676:SHA
Xizang Weixinkang Pharmaceutical Co Ltd
CNÂ¥8,83
-1,12%
(-0,10) 1D
15 Okt., 15:00:00 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 603676...
Open
CNÂ¥8,93
High
CNÂ¥8,93
Low
CNÂ¥8,79
Mkt. cap
3,91 mjd
Avg. vol.
1,59 m
Volume
1,34 m
Dividend
3,70%
Quarterly dividend
CNÂ¥0,08
Ex-dividend date
29 Jun. 2026
P/E ratio
19,82
52-wk high
CNÂ¥12,08
52-wk low
CNÂ¥7,82
EPS
CNÂ¥0,45
Shares outstanding
423,00 m
No. of employees
763
Open
CNÂ¥8,93
High
CNÂ¥8,93
Low
CNÂ¥8,79
Mkt. cap
3,91 mjd
Avg. vol.
1,59 m
Volume
1,34 m
Dividend
3,70%
Quarterly dividend
CNÂ¥0,08
Ex-dividend date
29 Jun. 2026
P/E ratio
19,82
52-wk high
CNÂ¥12,08
52-wk low
CNÂ¥7,82
EPS
CNÂ¥0,45
Shares outstanding
423,00 m
No. of employees
763
News stories
From web sources and news partners
About Xizang Weixinkang Pharmaceutical Co Ltd
CEO-
Employees763
Founded2002
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
276,24 m
273,33 m
322,14 m
262,14 m
Cost of goods sold
103,31 m
113,44 m
128,24 m
109,51 m
Cost of revenue
103,31 m
113,44 m
128,24 m
109,51 m
Research and development expenses
28,10 m
34,04 m
19,29 m
20,63 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
85,75 m
111,67 m
93,39 m
87,12 m
Operating expense
81,29 m
180,88 m
116,61 m
110,23 m
Total operating expenses
184,60 m
294,32 m
244,85 m
219,74 m
Operating income
91,65 m
-20,98 m
77,29 m
42,40 m
Other non operating income
10,90 k
-224,74 k
7,57 k
-160,84 k
EBT including unusual items
60,67 m
15,41 m
80,30 m
86,94 m
EBT excluding unusual items
95,80 m
-17,48 m
80,14 m
45,64 m
Income tax expense
24,28 m
1,73 m
11,96 m
12,35 m
Effective tax rate
40,02%
11,24%
14,89%
14,21%
Other operating expenses
-32,87 m
36,84 m
3,07 m
2,08 m
Net income
36,39 m
13,68 m
68,34 m
74,59 m
Net profit margin
13,17%
5,00%
21,21%
28,45%
Earnings per share
-
-
-
-
Interest and investment income
4,35 m
3,80 m
2,94 m
3,44 m
Interest expense
-84,28 k
-58,13 k
-98,46 k
-53,47 k
Net interest expenses
4,27 m
3,74 m
2,84 m
3,39 m
Depreciation and amortization charges
-
-
-
-
EBITDA
103,26 m
-10,17 m
88,10 m
53,19 m
Gain or loss from assets sale
88,96 k
80,57 k
-
4,48 k
AI content may include mistakes. Learn more
Google-programme